A Phase 2 interventional study of JNJ-55308942 and Placebo in Bipolar Disorder, sponsored by Janssen Pharmaceutica N.V., Belgium. Completed at 44 sites in 4 countries. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2025-07-11.
Sponsored by Janssen Pharmaceutica N.V., Belgium (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies in Bipolar Disorder by Johnson & Johnson — 2 open to participants now, 2 under way, 2 of them phase 3. Bipolar Disorder · Johnson & Johnson.
Among the 39 studies in Bipolar Disorder by Johnson & Johnson, this one is the 28th largest by enrollment of the 36 interventional ones that give a count, is the only one that started in 2022, is the only one in phase 2, and was the 35th registered.
1,687 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.
Browse Bipolar Disorder studies →2 of the 39 studies in Bipolar Disorder by Johnson & Johnson are open now, in 4 countries. Recruiting first, the newest first:
Intra-Cellular Therapies, Inc. · Sites in United States, Colombia, India and 1 more country
Ages 10–17
Intra-Cellular Therapies, Inc. · Sites in United States, Colombia, Serbia
Ages 5–17
By country, each count listing its studies:
Of the 207 Bipolar Disorder studies recruiting now, 60 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 116 is above the median of 64 across 1,282 interventional studies indexed under Bipolar Disorder.
Median enrollment 300 across the 36 interventional studies, 1,066 across the 3 observational. Of the 37 that completed or were terminated, 9 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Janssen Pharmaceutica N.V., Belgium, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Pharmaceutica N.V., Belgium is the lead sponsor of 58 studies on the registry; none are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 39 studies in Bipolar Disorder by Johnson & Johnson, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy of JNJ-55308942 compared to placebo on symptoms of depression in participants with bipolar disorder (BD) in a major depressive episode (MDE) at Week 6.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a JNJ-55308942 capsule once daily for 6 weeks.
Drug: JNJ-55308942
Participants will receive a matching placebo capsule once daily for 6 weeks.
Drug: Placebo
JNJ-55308942 capsules will be administered orally.
Matching placebo capsules will be administered orally.
Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Week 6
Change from baseline in MADRS total score up to Week 6 were reported. MADRS was a clinician-rated scale designed to measure depression severity and detect changes due to antidepressant (AD) treatment. The MADRS evaluated reported sadness, apparent sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. The scale consisted of 10 items, each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms),with higher score indicating a more severe condition. The MADRS total score was the sum of scores from individual question items and it ranged from 0 to 60, with higher scores indicated more severe conditions. Negative change in MADRS total score indicated improvement.
Time frame: From Baseline (Day 1) up to Week 6
Change From Baseline in Snaith-Hamilton Pleasure Scale (SHAPS) Total Score up to Week 6
Change from baseline in SHAPS total score up to Week 6 were reported. The SHAPS was a reliable, valid, and unidimensional instrument used to assess hedonic capacity in adults with Major Depressive Disorder. It is a 14-item, self-report tool with a completion time below 5 minutes. Each of the items had a set of 4 response categories: 1 = definitely agree/strongly agree, 2 = agree, 3 = disagree, and 4 = strongly disagree. The SHAPS total score was the sum of the 14 item scores, which ranged from 14 to 56. A higher SHAPS total score indicated higher levels of current anhedonia. Negative changes in the SHAPS total score indicated improvement.
Time frame: From Baseline (Day 1) up to Week 6
Change From Baseline in MADRS Total Score up to Week 6 (Genetic Subgroup Analysis)
Genetic subgroup analysis included participants with bipolar depression and who were with P2RX7 Gain of Function single nucleotide polymorphism (P2RX7 GoF SNP) mutation genotype: heterozygous or homozygous. MADRS was a clinician-rated scale designed to measure depression severity and detect changes due to AD treatment. The MADRS evaluated reported sadness, apparent sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. The scale consisted of 10 items, each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms),with higher score indicating a more severe condition. The MADRS total score was the sum of scores from individual question items and it ranged from 0 to 60, with higher scores indicated more severe conditions. Negative change in MADRS total score indicated improvement.
Time frame: From Baseline (Day 1) up to Week 6
Change From Baseline in MADRS Total Score up to Week 6 (Diagnosis Subgroup Analysis)
Change from baseline in MADRS total score up to Week 6 (Diagnosis Subgroup Analysis) were reported. Diagnosis subgroup analysis included participants with bipolar type 1 or II. MADRS was a clinician-rated scale designed to measure depression severity and detect changes due to AD treatment. The MADRS evaluated reported sadness, apparent sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. The scale consisted of 10 items, each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms),with higher score indicating a more severe condition. The MADRS total score was the sum of scores from individual question items and it ranged from 0 to 60, with higher scores indicated more severe conditions. Negative change in MADRS total score indicated improvement.
Time frame: From Baseline (Day 1) up to Week 6
Change From Baseline in MADRS Total Score up to Week 6 (Biomarker Subgroup Analysis)
Biomarker subgroup analysis included specific (3-Marker Model \[3MM\]) biomarker profile: Yes or No. 3MM biomarker profile was defined as serum C-reactive protein \>3 mg/Liter(L) and soluble interleukin-6 receptor \>25 micrograms(mcg)/L or tumor necrosis factor \>4 nanograms(ng)/L at baseline. MADRS was a clinician-rated scale designed to measure depression severity and detect changes due to AD treatment. MADRS evaluated reported sadness, apparent sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Scale consist of 10 items each of which was scored from 0(item not present or normal) to 6(severe or continuous presence of the symptoms),with higher score indicating a more severe condition. MADRS total score was sum of scores from individual question items, ranged from 0 to 60,with higher scores indicated more severe conditions. Negative change in MADRS total score indicated improvement.
Time frame: From Baseline (Day 1) up to Week 6
Number of Participants With Treatment-emergent Clinically Important Abnormalities in Vital Signs
Vital signs parameters included pulse rate (abnormally low \[AL\]: \<50 beats per minute \[bpm\] and with \>15 bpm decrease from baseline and abnormally high \[AH\]: \>100 bpm and with \>15 bpm increase from baseline), Systolic blood pressure (SBP) (AL: \<90 millimeters of mercury \[mmHg\] and with \>20 mmHg decrease from baseline and AH: \>180 mmHg and with \>20 mmHg increase from baseline), Diastolic blood pressure (DBP) (AL: \<50 mmHg and with \>15 mmHg decrease from baseline and AH: \>105 mmHg and with \>15 mmHg increase from baseline) , temperature (AL:\<35.5 and AH:\>37.5 degree Celsius \[C\]), respiratory rate (AH :\>20 breaths per minute), and weight (AL: decrease from baseline \>7% and AH: increase from baseline \>7%). Weight was planned to analyzed at Weeks 6 and 8 only. Treatment-emergent concluded if postbaseline value was above/below upper/lower limit and baseline value was below/above the upper/lower limit.
Time frame: Weeks 1, 2, 4, 6, and 8 (Follow-up/Early Withdrawal)
Change From Baseline in Clinical Laboratory Values in Male Hormone: Inhibin B
Change from baseline in clinical laboratory values in male hormone (Inhibin B) were reported.
Time frame: Baseline (Day 1), Week 4, 6, and 8 (Follow-up/Early Withdrawal)
Change From Baseline in Clinical Laboratory Values in Male Hormone: Luteinizing Hormone
Change from baseline in clinical laboratory values in male hormone (luteinizing hormone) were reported.
Time frame: Baseline (Day 1), Week 4, 6, and 8 (Follow-up/Early Withdrawal)
Change From Baseline in Clinical Laboratory Values in Male Hormone: Prolactin
Change from baseline in clinical laboratory values in male hormone (prolactin) were reported.
Time frame: Baseline (Day 1), Week 4, 6, and 8 (Follow-up/Early Withdrawal)
Change From Baseline in Clinical Laboratory Values in Male Hormones: Sex Hormone Binding Globulin, Testosterone (Free), Testosterone (High Sensitivity), and Testosterone (Low Sensitivity)
Change from baseline in clinical laboratory values in male hormones (sex hormone binding globulin, testosterone \[free\], testosterone \[high sensitivity\], and testosterone \[low sensitivity\]) were reported.
Time frame: Baseline (Day 1), Week 4, 6, and 8 (Follow-up/Early Withdrawal)
Number of Participants With Abnormal Laboratory Values: Serum Chemistry
Number of participants with abnormal laboratory values: serum chemistry were reported. It included: aspartate aminotransferase (high), alanine aminotransferase (high), bilirubin (high/low), and alkaline phosphatase (high/low). Only categories with data were reported.
Time frame: Weeks 2, 4, 6, and 8 (Follow-up/Early Withdrawal)
Number of Participants With Clinically Significant Abnormal Laboratory Values: Hematology
Number of participants with clinically significant abnormal laboratory values: hematology were reported.
Time frame: Weeks 2, 4, 6, and 8 (Follow-up/Early Withdrawal)
Number of Participants With Clinically Significant Abnormal Laboratory Values: Urinalysis
Number of participants with clinically significant abnormal laboratory values: urinalysis were reported.
Time frame: Weeks 2, 4, 6, and 8 (Follow-up/Early Withdrawal)
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Number of participants with TEAEs were reported. An adverse event (AE) is any untoward medical occurrence in a clinical study participants who administered a medicinal (investigational or non-investigational) product and does not necessarily have a causal relationship with the treatment. A TEAE defined as an AE that occurred at or after the first dose administration up to day of the last dose plus 30 days.
Time frame: Day 1 (Week 0) up to 30 days after the last dose (up to 11 weeks)
Number of Participants With Treatment-emergent Abnormalities in Electrocardiograms (ECGs)
Number of participants with treatment-emergent abnormalities in ECGs were reported. It included ECG mean heart rate (abnormally low \[AL\]: \<50 and abnormally high \[AH\]: \>100 beats per minute \[bpm\]), PR Interval (AL: \<120 and AH: \>200 milliseconds \[msec\]), QRS Duration (AL: \<60 and AH: \>120 msec), and QT Interval (AL: \<200 and AH: \>500 msec). A treatment-emergent abnormalities in ECGs are defined as those abnormalities that occurred at or after the first dose administration.
Time frame: Weeks 1, 2, 4, 6, and 8 (Follow-up/Early Withdrawal)
Change From Baseline in Young Mania Rating Scale (YMRS) Total Score
Change from baseline in YMRS total score were reported. The YMRS was designed to measure the severity of manic symptoms, to gauge the effect of treatment on mania severity, and to detect a return of manic symptoms (for example relapse or recurrence). YMRS had 11 items : 4 items (irritability, speech, thought content, and disruptive/aggressive behavior) were graded on a scale of 0 to 8 and the remaining 7 items (elevated mood, increased motor activity, sexual interest, sleep, language-thought disorder, appearance, and insight) were graded on a scale of 0 to 4. Higher scores indicated greater symptom severity. Responses were summed to yield YMRS total score ranged from 0 to 60 , with higher scores reflecting greater severity of mania.
Time frame: From Baseline (Day 1) up to Week 6
Number of Participants Who Reported Suicidal Ideation (SI) or Suicidal Behavior (SB) Using With Columbia Suicide Severity Rating Scale (C-SSRS) Score
C-SSRS is a clinician-rated instrument that reports severity of both suicidal ideation (SI) and suicidal behavior (SB). SI categories: 1 (wish to be dead), 2 (nonspecific active suicidal thoughts), 3 (active suicidal ideation with any methods \[not plan\] without intent to act), 4 (active SI with some intent to act, without specific plan), and 5 (active SI with specific plan and intent). SB categories: 6 (preparatory acts or behavior), 7 (aborted attempt), 8 (interrupted attempt), 9 (actual attempt), and 10 (suicide). An additional category for non-suicide: non-suicidal self-injurious behavior. SI/SB was indicated by a "yes" answer to any of the listed categories. Score of 0 (no SI or SB) was assigned. Maximum score of 1 to 10 was assigned if suicidal ideation or behavior was present. Scoring was grouped into 3 categories: No SI/SB (0), SI (score 1 to 5), and SB (score 6 to 10), with higher scores indicating more severe ideation/behavior.
Time frame: From Baseline (Day 1) up to Week 8
Change From Baseline in Clinical Global Impression-Severity Scale (CGI-S) Score
Change from baseline in CGI-S score were reported. The CGI-S provides an overall clinician-determined summary measure of the severity of the participant's illness that takes into account all available information, including knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. The CGI-S is a 7-point global assessment scale that measures the clinician's impression of the severity of mental illness exhibited by a participant, and rated on a scale of 1 to 7: 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; and 7=among the most extremely ill participants. Higher scores indicate worsening. Negative change in CGI-S score indicate improvement.
Time frame: From Baseline (Day 1) up to Week 6
Plasma Concentrations of JNJ-55308942
Plasma concentrations of JNJ-55308942 were reported.
Time frame: Predose, 1.5 hours and 4 hours post-dose on Week 0 (Day 1), Weeks 1 (Day 8), 2 (Day 15), 4 (Day 29), and 6 (Day 43)
Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Score - Ability to Participate in Social Roles and Activities (APS) T-Scores
Change from baseline in PROMIS score - ability to participate in social roles and activities T-Scores were reported. The PROMIS - APS item bank assessed the perceived ability to perform one's usual social roles and activities. The item bank did not use a time frame (for example, over the past seven days) when assessing the APS. The Short Form 4a included 4 items that represent this concept. Each question had 5 response options ranging in value from 1 to 5 with higher scores indicating better social function. The total raw score for the short form was calculated by summing the values of the response to each question, so for the 4-item form, the lowest possible raw score was 4; the highest possible raw score was 20. The total raw score was converted to a T score with a mean of 50 and a standard deviation of 10. Higher T-scores indicate better social function.
Time frame: Baseline (Day 1), Weeks 1, 2, 3, 4, 5, and 6
Change From Baseline in Patient Health Questionnaire-9 (PHQ-9) Total Score
Change from baseline in PHQ-9 total score were reported. PHQ-9 is 9-item, self-report scale assessed depressive symptoms. Each item was rated on 4-point scale (0=Not at all, 1=several days, 2=more than half days, 3=nearly every day. The participant's item responses were summed to provide PHQ-9 total score (range of 0 to 27) with higher scores indicating greater severity of depressive symptoms.
Time frame: Baseline (Day 1), Weeks 1, 2, 3, 4, 5, and 6
Change From Baseline in Generalized Anxiety Disorder 7 (GAD-7) Total Score
Change from baseline in GAD-7 total score were reported. GAD-7 is a brief and validated 7-item self-reported questionnaire for assessment of overall GAD. Participants responded to each item using a 4-point scale with response categories of 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day, with a higher score representing a more severe condition. Item responses were summed to yield GAD-7 total score which ranged of 0 to 21, where higher scores indicated more anxiety.
Time frame: Baseline (Day 1), Weeks 2, 4, and 6
Number of Participants Who Achieved Response at Week 6
Number of participants who achieved response at Week 6 were reported. Response was defined as greater than or equal to (\>=)50% improvement in MADRS total score from baseline. MADRS was a clinician-rated scale designed to measure depression severity and detect changes due to AD treatment. The MADRS evaluated reported sadness, apparent sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. The scale consisted of 10 items, each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms),with higher score indicating a more severe condition. The MADRS total score was the sum of scores from individual question items and it ranged from 0 to 60, with higher scores indicated more severe conditions. Negative change in MADRS total score indicated improvement.
Time frame: Week 6
Number of Participants Who Achieved Remission at Week 6
Number of participants who achieved remission at Week 6 were reported. Remission was defined as MADRS total score \<=12. MADRS was a clinician-rated scale designed to measure depression severity and detect changes due to AD treatment. The MADRS evaluated reported sadness, apparent sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. The scale consisted of 10 items, each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms),with higher score indicating a more severe condition. The MADRS total score was the sum of scores from individual question items and it ranged from 0 to 60, with higher scores indicated more severe conditions. Negative change in MADRS total score indicated improvement.
Time frame: Week 6
Change From Baseline in MADRS Total Score up to Week 6 (Subgroup of Participants With Messenger Ribonucleic Acid [mRNA] Transcript Levels)
Change from baseline in MADRS total score up to Week 6 (subgroup of participants with mRNA transcript levels) was planned to be reported. Subgroup included participants with mRNA transcript levels at baseline that exceeded the medium level for both P2RX7 and IL-1-beta. MADRS was a clinician-rated scale designed to measure depression severity and detect changes due to AD treatment. MADRS evaluated reported sadness, apparent sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. The scale consisted of 10 items, each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms),with higher score indicating a more severe condition. MADRS total score was the sum of scores from individual question items and it ranged from 0 to 60, with higher scores indicated more severe conditions. Negative change in MADRS total score indicated improvement.
Time frame: From Baseline (Day 1) up to Week 6
Change From Baseline in MADRS Total Score up to Week 6 (Concomitant Medication Subgroup Analysis)
Change from baseline in MADRS total score up to Week 6 (concomitant medication subgroup analysis) was reported. Concomitant medication subgroup analysis included subjects with BD not taking any mood stabilizer or antipsychotic, taking a mood stabilizer alone, taking antipsychotic alone, and taking a combination of mood stabilizer and an antipsychotic. MADRS measures depression severity, detects changes due to AD treatment. It consists of 10 items (evaluate apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thoughts), scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed to total possible score of 0 to 60. Higher scores indicate more severe conditions. Negative change in score indicates improvement.
Time frame: From Baseline (Day 1) up to Week 6
| Milestone | JNJ-55308942 | Placebo |
|---|---|---|
| Started | 55 | 61 |
| Treated (safety analysis set) | 54 | 60 |
| Completed | 42 | 50 |
| Not completed | 13 | 11 |
| Withdrew: Adverse event | 5 | 7 |
| Withdrew: Withdrawal by subject | 4 | 3 |
| Withdrew: Lack of efficacy | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Randomized but not treated | 1 | 1 |
Change from baseline in MADRS total score up to Week 6 were reported. MADRS was a clinician-rated scale designed to measure depression severity and detect changes due to antidepressant (AD) treatment. The MADRS evaluated reported sadness, apparent sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. The scale consisted of 10 items, each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms),with higher score indicating a more severe condition. The MADRS total score was the sum of scores from individual question items and it ranged from 0 to 60, with higher scores indicated more severe conditions. Negative change in MADRS total score indicated improvement.
| Units on a scale | JNJ-55308942 | Placebo |
|---|---|---|
| Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Week 6 | -16.0 ± 10.43 | -15.4 ± 9.81 |
Change from baseline in SHAPS total score up to Week 6 were reported. The SHAPS was a reliable, valid, and unidimensional instrument used to assess hedonic capacity in adults with Major Depressive Disorder. It is a 14-item, self-report tool with a completion time below 5 minutes. Each of the items had a set of 4 response categories: 1 = definitely agree/strongly agree, 2 = agree, 3 = disagree, and 4 = strongly disagree. The SHAPS total score was the sum of the 14 item scores, which ranged from 14 to 56. A higher SHAPS total score indicated higher levels of current anhedonia. Negative changes in the SHAPS total score indicated improvement.
| Units on a scale | JNJ-55308942 | Placebo |
|---|---|---|
| Change From Baseline in Snaith-Hamilton Pleasure Scale (SHAPS) Total Score up to Week 6 | -8.2 ± 6.87 | -8.3 ± 8.69 |
Genetic subgroup analysis included participants with bipolar depression and who were with P2RX7 Gain of Function single nucleotide polymorphism (P2RX7 GoF SNP) mutation genotype: heterozygous or homozygous. MADRS was a clinician-rated scale designed to measure depression severity and detect changes due to AD treatment. The MADRS evaluated reported sadness, apparent sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. The scale consisted of 10 items, each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms),with higher score indicating a more severe condition. The MADRS total score was the sum of scores from individual question items and it ranged from 0 to 60, with higher scores indicated more severe conditions. Negative change in MADRS total score indicated improvement.
| Units on a scale | JNJ-55308942 | Placebo |
|---|---|---|
| P2RX7 GoF SNP mutation genotype: Heterozygous | -15.2 ± 9.45 | -16.5 ± 10.22 |
| P2RX7 GoF SNP mutation genotype: Homozygous | -18.2 ± 13.06 | -13.1 ± 8.75 |
Change from baseline in MADRS total score up to Week 6 (Diagnosis Subgroup Analysis) were reported. Diagnosis subgroup analysis included participants with bipolar type 1 or II. MADRS was a clinician-rated scale designed to measure depression severity and detect changes due to AD treatment. The MADRS evaluated reported sadness, apparent sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. The scale consisted of 10 items, each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms),with higher score indicating a more severe condition. The MADRS total score was the sum of scores from individual question items and it ranged from 0 to 60, with higher scores indicated more severe conditions. Negative change in MADRS total score indicated improvement.
| Units on a scale | JNJ-55308942 | Placebo |
|---|---|---|
| Bipolar type I | -15.5 ± 11.02 | -15.3 ± 10.06 |
| Bipolar type II | -17.7 ± 8.20 | -15.7 ± 9.47 |
Biomarker subgroup analysis included specific (3-Marker Model \[3MM\]) biomarker profile: Yes or No. 3MM biomarker profile was defined as serum C-reactive protein \>3 mg/Liter(L) and soluble interleukin-6 receptor \>25 micrograms(mcg)/L or tumor necrosis factor \>4 nanograms(ng)/L at baseline. MADRS was a clinician-rated scale designed to measure depression severity and detect changes due to AD treatment. MADRS evaluated reported sadness, apparent sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Scale consist of 10 items each of which was scored from 0(item not present or normal) to 6(severe or continuous presence of the symptoms),with higher score indicating a more severe condition. MADRS total score was sum of scores from individual question items, ranged from 0 to 60,with higher scores indicated more severe conditions. Negative change in MADRS total score indicated improvement.
| Units on a scale | JNJ-55308942 | Placebo |
|---|---|---|
| 3MM biomarker profile: Yes | -12.5 ± 9.04 | -13.9 ± 10.77 |
| 3MM biomarker profile: No | -17.2 ± 10.75 | -16.6 ± 9.17 |
Vital signs parameters included pulse rate (abnormally low \[AL\]: \<50 beats per minute \[bpm\] and with \>15 bpm decrease from baseline and abnormally high \[AH\]: \>100 bpm and with \>15 bpm increase from baseline), Systolic blood pressure (SBP) (AL: \<90 millimeters of mercury \[mmHg\] and with \>20 mmHg decrease from baseline and AH: \>180 mmHg and with \>20 mmHg increase from baseline), Diastolic blood pressure (DBP) (AL: \<50 mmHg and with \>15 mmHg decrease from baseline and AH: \>105 mmHg and with \>15 mmHg increase from baseline) , temperature (AL:\<35.5 and AH:\>37.5 degree Celsius \[C\]), respiratory rate (AH :\>20 breaths per minute), and weight (AL: decrease from baseline \>7% and AH: increase from baseline \>7%). Weight was planned to analyzed at Weeks 6 and 8 only. Treatment-emergent concluded if postbaseline value was above/below upper/lower limit and baseline value was below/above the upper/lower limit.
| Participants | JNJ-55308942 | Placebo |
|---|---|---|
| Pulse (beats per minutes [bpm]): <50 bpm and with >15 bpm decrease from baseline: Week 1 | 0 (9.04 to —) | 0 (10.77 to —) |
| Pulse (bpm): >100 bpm and with >15 bpm increase from baseline: Week 1 | 0 (10.75 to —) | 0 (9.17 to —) |
| SBP (millimeters of mercury [mmHg]): <90 mmHg and with >20 mmHg decrease from baseline: Week 1 | 0 | 0 |
| SBP (mmHg): >180 mmHg and with >20 mmHg increase from baseline: Week 1 | 0 | 0 |
| DBP (mmHg): <50 mmHg and with >15 mmHg decrease from baseline : Week 1 | 0 | 0 |
| DBP (mmHg): >105 mmHg and with >15 mmHg increase from baseline: Week 1 | 0 | 0 |
| Temperature (degree Celsius [C]): <35.5 degree C: Week 1 | 0 | 0 |
| Temperature (degree C): >37.5 degree C: Week 1 | 0 | 0 |
| Respiratory Rate: >20 breaths per minute: Week 1 | 0 | 0 |
| Pulse: <50 bpm and with >15 bpm decrease from baseline: Week 2 | 0 | 0 |
| Pulse: >100 bpm and with >15 bpm increase from baseline: Week 2 | 0 | 0 |
| SBP:<90 mmHg and with >20 mmHg decrease from baseline: Week 2 | 0 | 0 |
| SBP: >180 mmHg and with >20 mmHg increase from baseline: Week 2 | 0 | 0 |
| DBP: <50 mmHg and with >15 mmHg decrease from baseline: Week 2 | 0 | 0 |
| DBP: >105 mmHg and with >15 mmHg increase from baseline: Week 2 | 0 | 0 |
| Temperature (degree C): <35.5 degree C: Week 2 | 0 | 0 |
| Temperature (degree C): >37.5 degree C: Week 2 | 0 | 0 |
| Respiratory Rate: >20 breaths per minute: Week 2 | 0 | 1 |
| Pulse (bpm): <50 bpm and with >15 bpm decrease from baseline: Week 4 | 0 | 0 |
| Pulse (bpm): >100 bpm and with >15 bpm increase from baseline: Week 4 | 0 | 0 |
| SBP (mmHg): <90 mmHg and with >20 mmHg decrease from baseline: Week 4 | 0 | 0 |
| SBP (mmHg): >180 mmHg and with >20 mmHg increase from baseline: Week 4 | 0 | 0 |
| DBP (mmHg): <50 mmHg and with >15 mmHg decrease from baseline: Week 4 | 0 | 0 |
| DBP (mmHg): <105 mmHg and with >15 mmHg increase from baseline: Week 4 | 0 | 0 |
| Temperature (degree C): <35.5 degree C: Week 4 | 0 | 0 |
| Temperature (degree C): >37.5 degree C: Week 4 | 0 | 0 |
| Respiratory Rate: >20 breaths per minute: Week 4 | 0 | 0 |
| Pulse: <50 bpm and with >15 bpm decrease from baseline: Week 6 | 0 | 0 |
| Pulse: <100 bpm and with >15 bpm increase from baseline: Week 6 | 0 | 0 |
| SBP (mmHg): <90 mmHg and with >20 mmHg decrease from baseline: Week 6 | 0 | 0 |
| SBP (mmHg): >180 mmHg and with >20 mmHg increase from baseline: Week 6 | 0 | 0 |
| DBP (mmHg): <50 mmHg and with >15 mmHg decrease from baseline: Week 6 | 0 | 0 |
| DBP (mmHg): >105 mmHg and with >15 mmHg increase from baseline: Week 6 | 0 | 0 |
| Temperature (C): <35.5 degree C: Week 6 | 0 | 0 |
| Temperature (degree C): <37.5 degree C: Week 6 | 0 | 0 |
| Respiratory Rate (breaths/min): >20 breaths per minute: Week 6 | 0 | 0 |
| Weight (kg): Decrease from baseline >7%: Week 6 | 0 | 0 |
| Weight (kg): Increase from baseline >7%: Week 6 | 0 | 1 |
| Pulse: <50 bpm and with >15 bpm decrease from baseline: Follow-up (Week 8) | 0 | 0 |
| Pulse: >100 bpm and with >15 bpm increase from baseline: Follow-up (Week 8) | 1 | 0 |
| SBP (mmHg): <90mmHg and with >20 mmHg decrease from baseline: Follow-up (Week 8) | 0 | 0 |
| SBP (mmHg):>180mmHg and with >20 mmHg increase from baseline: Follow-up (Week 8) | 0 | 1 |
| DBP (mmHg): <50mmHg and with >15mmHg decrease from baseline: Follow-up (Week 8) | 0 | 0 |
| DBP (mmHg):>105mmHg and with >15mmHg increase from baseline: Follow-up (Week 8) | 0 | 1 |
| Temperature (C): <35.5 degree C: Follow-up (Week 8) | 0 | 0 |
| Temperature (C): >37.5 degree C: Follow-up (Week 8) | 0 | 0 |
| Respiratory Rate (breaths/min): >20 breaths per minute: Follow-up (Week 8) | 0 | 0 |
| Weight (kg): Decrease from baseline >7%: Follow-up (Week 8) | 1 | 0 |
| Weight (kg): Increase from baseline >7%: Follow-up (Week 8) | 0 | 2 |
Change from baseline in clinical laboratory values in male hormone (Inhibin B) were reported.
| nanograms per liter (ng/L) | JNJ-55308942 | Placebo |
|---|---|---|
| Week 4 | -5.9 ± 30.45 | 3.1 ± 22.15 |
| Week 6 | -2.1 ± 30.02 | -1.8 ± 31.09 |
| Week 8 | -1.2 ± 28.25 | 7.3 ± 19.60 |
Change from baseline in clinical laboratory values in male hormone (luteinizing hormone) were reported.
| International units per liter (IU/L) | JNJ-55308942 | Placebo |
|---|---|---|
| Week 4 | 0.15 ± 1.814 | 0.29 ± 1.513 |
| Week 6 | -0.11 ± 1.677 | 0.63 ± 2.719 |
| Week 8 | -0.35 ± 1.638 | 0.84 ± 2.103 |
Change from baseline in clinical laboratory values in male hormone (prolactin) were reported.
| micrograms per liter (mcg/L) | JNJ-55308942 | Placebo |
|---|---|---|
| Week 4 | 0.347 ± 2.4360 | 1.803 ± 3.6211 |
| Week 6 | 0.551 ± 3.1575 | 1.465 ± 5.3742 |
| Week 8 | -0.160 ± 3.8622 | 1.748 ± 3.9231 |
Change from baseline in clinical laboratory values in male hormones (sex hormone binding globulin, testosterone \[free\], testosterone \[high sensitivity\], and testosterone \[low sensitivity\]) were reported.
| nanomoles per liter (nmol/L) | JNJ-55308942 | Placebo |
|---|---|---|
| Sex Hormone Binding Globulin: Week 4 | -1.976 ± 7.1297 | -0.574 ± 8.5796 |
| Sex Hormone Binding Globulin: Week 6 | -4.020 ± 7.4992 | -0.274 ± 9.2454 |
| Sex Hormone Binding Globulin: Week 8 | -2.520 ± 7.8489 | 1.058 ± 6.6109 |
| Testosterone, Free: Week 4 | 0.005 ± 0.0677 | 0.030 ± 0.0995 |
| Testosterone, Free: Week 6 | -0.010 ± 0.0731 | 0.037 ± 0.1084 |
| Testosterone, Free: Week 8 | 0.031 ± 0.0763 | 0.046 ± 0.0877 |
| Testosterone, High Sensitivity: Week 4 | -0.797 ± 3.3271 | 0.357 ± 5.5917 |
| Testosterone, High Sensitivity: Week 6 | -1.262 ± 3.6807 | 0.842 ± 5.6815 |
| Testosterone, High Sensitivity: Week 8 | 0.604 ± 3.7718 | 1.416 ± 4.3083 |
| Testosterone, Low Sensitivity: Week 4 | -0.791 ± 3.8886 | 0.854 ± 5.9616 |
| Testosterone, Low Sensitivity: Week 6 | -1.532 ± 4.5203 | 1.380 ± 5.9515 |
| Testosterone, Low Sensitivity: Week 8 | 1.116 ± 4.8452 | 1.728 ± 4.6578 |
Number of participants with abnormal laboratory values: serum chemistry were reported. It included: aspartate aminotransferase (high), alanine aminotransferase (high), bilirubin (high/low), and alkaline phosphatase (high/low). Only categories with data were reported.
| Participants | JNJ-55308942 | Placebo |
|---|---|---|
| Aspartate Aminotransferase (High): Week 2 | 2 | 2 |
| Aspartate Aminotransferase (High): Week 4 | 0 | 2 |
| Aspartate Aminotransferase (High): Week 6 | 1 | 0 |
| Aspartate Aminotransferase (High): Week 8 | 0 | 2 |
| Alanine Aminotransferase (High): Week 2 | 1 | 3 |
| Alanine Aminotransferase (High): Week 4 | 2 | 3 |
| Alanine Aminotransferase (High): Week 6 | 2 | 1 |
| Alanine Aminotransferase (High): Week 8 | 1 | 2 |
| Bilirubin (Low): Week 2 | 4 | 9 |
| Bilirubin (High): Week 2 | 1 | 0 |
| Bilirubin (Low): Week 4 | 8 | 7 |
| Bilirubin (Low): Week 6 | 5 | 4 |
| Bilirubin (High): Week 6 | 2 | 0 |
| Bilirubin (Low): Week 8 | 3 | 5 |
| Bilirubin (High): Week 8 | 1 | 0 |
| Alkaline Phosphatase (Low): Week 2 | 1 | 0 |
| Alkaline Phosphatase (High): Week 2 | 3 | 5 |
| Alkaline Phosphatase (Low): Week 4 | 1 | 0 |
| Alkaline Phosphatase (High): Week 4 | 0 | 3 |
| Alkaline Phosphatase (Low): Week 6 | 1 | 0 |
| Alkaline Phosphatase (High): Week 6 | 1 | 6 |
| Alkaline Phosphatase (Low): Week 8 | 1 | 0 |
| Alkaline Phosphatase (High): Week 8 | 4 | 5 |
Number of participants with clinically significant abnormal laboratory values: hematology were reported.
| Participants | JNJ-55308942 | Placebo |
|---|---|---|
| Week 2 | 0 | 0 |
| Week 4 | 0 | 0 |
| Week 6 | 0 | 0 |
| Week 8 | 0 | 0 |
Number of participants with clinically significant abnormal laboratory values: urinalysis were reported.
| Participants | JNJ-55308942 | Placebo |
|---|---|---|
| Week 2 | 0 | 0 |
| Week 4 | 0 | 0 |
| Week 6 | 0 | 0 |
| Week 8 | 0 | 0 |
Number of participants with TEAEs were reported. An adverse event (AE) is any untoward medical occurrence in a clinical study participants who administered a medicinal (investigational or non-investigational) product and does not necessarily have a causal relationship with the treatment. A TEAE defined as an AE that occurred at or after the first dose administration up to day of the last dose plus 30 days.
| Participants | JNJ-55308942 | Placebo |
|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 22 | 28 |
Number of participants with treatment-emergent abnormalities in ECGs were reported. It included ECG mean heart rate (abnormally low \[AL\]: \<50 and abnormally high \[AH\]: \>100 beats per minute \[bpm\]), PR Interval (AL: \<120 and AH: \>200 milliseconds \[msec\]), QRS Duration (AL: \<60 and AH: \>120 msec), and QT Interval (AL: \<200 and AH: \>500 msec). A treatment-emergent abnormalities in ECGs are defined as those abnormalities that occurred at or after the first dose administration.
| Participants | JNJ-55308942 | Placebo |
|---|---|---|
| ECG Mean Heart Rate: <50 bpm: Week 1 | 1 | 0 |
| ECG Mean Heart Rate: >100 bpm: Week 1 | 0 | 0 |
| PR Interval: <120 msec: Week 1 | 0 | 1 |
| PR Interval: >200 msec: Week 1 | 1 | 0 |
| QRS Duration: <60 msec: Week 1 | 0 | 1 |
| QRS Duration: >120 msec: Week 1 | 1 | 0 |
| QT Interval: <200 msec: Week 1 | 0 | 0 |
| QT Interval: >500 msec: Week 1 | 0 | 0 |
| ECG Mean Heart Rate: <50 bpm: Week 2 | 0 | 0 |
| ECG Mean Heart Rate: >100 bpm: Week 2 | 1 | 1 |
| PR Interval: <120 msec: Week 2 | 0 | 0 |
| PR Interval: >200 msec: Week 2 | 1 | 2 |
| QRS Duration: <60 msec: Week 2 | 0 | 1 |
| QRS Duration: >120 msec: Week 2 | 0 | 1 |
| QT Interval: <200 msec: Week 2 | 0 | 0 |
| QT Interval: >500 msec: Week 2 | 0 | 0 |
| ECG Mean Heart Rate: <50 bpm: Week 4 | 0 | 0 |
| ECG Mean Heart Rate: >100 bpm: Week 4 | 1 | 0 |
| PR Interval: <120 msec: Week 4 | 0 | 1 |
| PR Interval: >200 msec: Week 4 | 0 | 0 |
| QRS Duration: <60 msec: Week 4 | 0 | 1 |
| QRS Duration: >120 msec: Week 4 | 1 | 0 |
| QT Interval: <200 msec: Week 4 | 0 | 0 |
| QT Interval: >500 msec: Week 4 | 0 | 0 |
| ECG Mean Heart Rate: <50 bpm: Week 6 | 0 | 0 |
| ECG Mean Heart Rate: >100 bpm: Week 6 | 0 | 0 |
| PR Interval: <120 msec: Week 6 | 0 | 0 |
| PR Interval: >200 msec: Week 6 | 0 | 0 |
| QRS Duration: <60 msec: Week 6 | 0 | 4 |
| QRS Duration: >120 msec: Week 6 | 0 | 0 |
| QT Interval: <200 msec: Week 6 | 0 | 0 |
| QT Interval: >500 msec: Week 6 | 0 | 0 |
| ECG Mean Heart Rate: <50 bpm: Week 8 | 0 | 0 |
| ECG Mean Heart Rate: >100 bpm: Week 8 | 0 | 0 |
| PR Interval: <120 msec: Week 8 | 1 | 0 |
| PR Interval: >200 msec: Week 8 | 0 | 0 |
| QRS Duration: <60 msec: Week 8 | 1 | 2 |
| QRS Duration: >120 msec: Week 8 | 0 | 1 |
| QT Interval: <200 msec: Week 8 | 0 | 0 |
| QT Interval: >500 msec: Week 8 | 0 | 0 |
Change from baseline in YMRS total score were reported. The YMRS was designed to measure the severity of manic symptoms, to gauge the effect of treatment on mania severity, and to detect a return of manic symptoms (for example relapse or recurrence). YMRS had 11 items : 4 items (irritability, speech, thought content, and disruptive/aggressive behavior) were graded on a scale of 0 to 8 and the remaining 7 items (elevated mood, increased motor activity, sexual interest, sleep, language-thought disorder, appearance, and insight) were graded on a scale of 0 to 4. Higher scores indicated greater symptom severity. Responses were summed to yield YMRS total score ranged from 0 to 60 , with higher scores reflecting greater severity of mania.
| Units on a scale | JNJ-55308942 | Placebo |
|---|---|---|
| Change From Baseline in Young Mania Rating Scale (YMRS) Total Score | -1.2 ± 2.23 | -1.1 ± 1.81 |
C-SSRS is a clinician-rated instrument that reports severity of both suicidal ideation (SI) and suicidal behavior (SB). SI categories: 1 (wish to be dead), 2 (nonspecific active suicidal thoughts), 3 (active suicidal ideation with any methods \[not plan\] without intent to act), 4 (active SI with some intent to act, without specific plan), and 5 (active SI with specific plan and intent). SB categories: 6 (preparatory acts or behavior), 7 (aborted attempt), 8 (interrupted attempt), 9 (actual attempt), and 10 (suicide). An additional category for non-suicide: non-suicidal self-injurious behavior. SI/SB was indicated by a "yes" answer to any of the listed categories. Score of 0 (no SI or SB) was assigned. Maximum score of 1 to 10 was assigned if suicidal ideation or behavior was present. Scoring was grouped into 3 categories: No SI/SB (0), SI (score 1 to 5), and SB (score 6 to 10), with higher scores indicating more severe ideation/behavior.
| Participants | JNJ-55308942 | Placebo |
|---|---|---|
| Suicidal ideation | 3 | 6 |
| Suicidal behavior | 1 | 0 |
| No SI/SB | 49 (2.23 to —) | 53 (1.81 to —) |
Change from baseline in CGI-S score were reported. The CGI-S provides an overall clinician-determined summary measure of the severity of the participant's illness that takes into account all available information, including knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. The CGI-S is a 7-point global assessment scale that measures the clinician's impression of the severity of mental illness exhibited by a participant, and rated on a scale of 1 to 7: 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; and 7=among the most extremely ill participants. Higher scores indicate worsening. Negative change in CGI-S score indicate improvement.
| Units on a scale | JNJ-55308942 | Placebo |
|---|---|---|
| Change From Baseline in Clinical Global Impression-Severity Scale (CGI-S) Score | -1.9 ± 1.49 | -1.7 ± 1.32 |
Plasma concentrations of JNJ-55308942 were reported.
| Nanograms per milliliter (ng/mL) | JNJ-55308942 |
|---|---|
| Week 0 (Day 1): Predose | 0.00 ± 0.000 |
| Week 0 (Day 1): 1.5 hours postdose | 406.13 ± 162.407 |
| Week 0 (Day 1): 4 hours postdose | 407.72 ± 133.461 |
| Week 1 (Day 8): Predose | 531.20 ± 200.351 |
| Week 1 (Day 8): 1.5 hours postdose | 868.01 ± 296.255 |
| Week 1 (Day 8): 4 hours postdose | 892.54 ± 219.210 |
| Week 2 (Day 15): Predose | 561.32 ± 194.184 |
| Week 2 (Day 15): 1.5 hours postdose | 930.59 ± 265.581 |
| Week 2 (Day 15): 4 hours postdose | 919.86 ± 213.028 |
| Week 4 (Day 29): Predose | 528.90 ± 144.580 |
| Week 4 (Day 29): 1.5 hours postdose | 885.50 ± 249.562 |
| Week 4 (Day 29): 4 hours postdose | 872.80 ± 208.734 |
| Week 6 (Day 43): Predose | 535.80 ± 160.568 |
| Week 6 (Day 43): 1.5 hours postdose | 862.31 ± 240.540 |
| Week 6 (Day 43): 4 hours postdose | 883.51 ± 209.413 |
Change from baseline in PROMIS score - ability to participate in social roles and activities T-Scores were reported. The PROMIS - APS item bank assessed the perceived ability to perform one's usual social roles and activities. The item bank did not use a time frame (for example, over the past seven days) when assessing the APS. The Short Form 4a included 4 items that represent this concept. Each question had 5 response options ranging in value from 1 to 5 with higher scores indicating better social function. The total raw score for the short form was calculated by summing the values of the response to each question, so for the 4-item form, the lowest possible raw score was 4; the highest possible raw score was 20. The total raw score was converted to a T score with a mean of 50 and a standard deviation of 10. Higher T-scores indicate better social function.
| T-score | JNJ-55308942 | Placebo |
|---|---|---|
| PROMIS-APS T-score: Week 1 | 2.51 ± 5.682 | 1.69 ± 6.859 |
| PROMIS-APS T-score: Week 2 | 5.33 ± 6.901 | 4.49 ± 9.174 |
| PROMIS-APS T-score: Week 3 | 6.52 ± 8.226 | 5.00 ± 8.884 |
| PROMIS-APS T-score: Week 4 | 9.12 ± 9.018 | 6.07 ± 8.369 |
| PROMIS-APS T-score: Week 5 | 9.47 ± 8.248 | 4.90 ± 9.296 |
| PROMIS-APS T-score: Week 6 | 10.50 ± 8.211 | 6.12 ± 8.412 |
Change from baseline in PHQ-9 total score were reported. PHQ-9 is 9-item, self-report scale assessed depressive symptoms. Each item was rated on 4-point scale (0=Not at all, 1=several days, 2=more than half days, 3=nearly every day. The participant's item responses were summed to provide PHQ-9 total score (range of 0 to 27) with higher scores indicating greater severity of depressive symptoms.
| Units on a scale | JNJ-55308942 | Placebo |
|---|---|---|
| Week 1 | -2.8 ± 4.24 | -3.1 ± 5.45 |
| Week 2 | -5.2 ± 5.64 | -4.7 ± 6.63 |
| Week 3 | -6.4 ± 6.25 | -5.1 ± 6.90 |
| Week 4 | -7.0 ± 6.38 | -6.1 ± 6.81 |
| Week 5 | -8.2 ± 6.59 | -5.2 ± 7.21 |
| Week 6 | -9.0 ± 6.79 | -7.0 ± 7.41 |
Change from baseline in GAD-7 total score were reported. GAD-7 is a brief and validated 7-item self-reported questionnaire for assessment of overall GAD. Participants responded to each item using a 4-point scale with response categories of 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day, with a higher score representing a more severe condition. Item responses were summed to yield GAD-7 total score which ranged of 0 to 21, where higher scores indicated more anxiety.
| Units on a scale | JNJ-55308942 | Placebo |
|---|---|---|
| Week 2 | -3.8 ± 5.08 | -4.2 ± 5.76 |
| Week 4 | -5.0 ± 6.59 | -4.5 ± 5.14 |
| Week 6 | -5.7 ± 6.21 | -5.7 ± 5.77 |
Number of participants who achieved response at Week 6 were reported. Response was defined as greater than or equal to (\>=)50% improvement in MADRS total score from baseline. MADRS was a clinician-rated scale designed to measure depression severity and detect changes due to AD treatment. The MADRS evaluated reported sadness, apparent sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. The scale consisted of 10 items, each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms),with higher score indicating a more severe condition. The MADRS total score was the sum of scores from individual question items and it ranged from 0 to 60, with higher scores indicated more severe conditions. Negative change in MADRS total score indicated improvement.
| Participants | JNJ-55308942 | Placebo |
|---|---|---|
| Number of Participants Who Achieved Response at Week 6 | 27 (6.21 to —) | 31 (5.77 to —) |
Number of participants who achieved remission at Week 6 were reported. Remission was defined as MADRS total score \<=12. MADRS was a clinician-rated scale designed to measure depression severity and detect changes due to AD treatment. The MADRS evaluated reported sadness, apparent sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. The scale consisted of 10 items, each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms),with higher score indicating a more severe condition. The MADRS total score was the sum of scores from individual question items and it ranged from 0 to 60, with higher scores indicated more severe conditions. Negative change in MADRS total score indicated improvement.
| Participants | JNJ-55308942 | Placebo |
|---|---|---|
| Number of Participants Who Achieved Remission at Week 6 | 25 (6.21 to —) | 30 (5.77 to —) |
Change from baseline in MADRS total score up to Week 6 (subgroup of participants with mRNA transcript levels) was planned to be reported. Subgroup included participants with mRNA transcript levels at baseline that exceeded the medium level for both P2RX7 and IL-1-beta. MADRS was a clinician-rated scale designed to measure depression severity and detect changes due to AD treatment. MADRS evaluated reported sadness, apparent sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. The scale consisted of 10 items, each of which was scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms),with higher score indicating a more severe condition. MADRS total score was the sum of scores from individual question items and it ranged from 0 to 60, with higher scores indicated more severe conditions. Negative change in MADRS total score indicated improvement.
| Units on a scale | JNJ-55308942 | Placebo |
|---|---|---|
| Change From Baseline in MADRS Total Score up to Week 6 (Subgroup of Participants With Messenger Ribonucleic Acid [mRNA] Transcript Levels) | NA ± NA | NA ± NA |
Change from baseline in MADRS total score up to Week 6 (concomitant medication subgroup analysis) was reported. Concomitant medication subgroup analysis included subjects with BD not taking any mood stabilizer or antipsychotic, taking a mood stabilizer alone, taking antipsychotic alone, and taking a combination of mood stabilizer and an antipsychotic. MADRS measures depression severity, detects changes due to AD treatment. It consists of 10 items (evaluate apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thoughts), scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed to total possible score of 0 to 60. Higher scores indicate more severe conditions. Negative change in score indicates improvement.
| Units on a scale | JNJ-55308942 | Placebo |
|---|---|---|
| Concomitant medication status: Not taking any mood stabilizer or antipsychotic | -15.5 ± 13.18 | -16.2 ± 9.69 |
| Concomitant medication status: Taking a mood stabilizer alone | -16.3 ± 9.82 | -15.6 ± 9.47 |
| Concomitant medication status: Taking an antipsychotic alone | -13.0 ± NA | 5.0 ± NA |
| Concomitant medication status: Taking a combination of a mood stabilizer and an antipsychotic | -13.0 ± NA | — |
Collected over All-cause mortality: From screening (-28 days) up to end of study (up to 12 weeks); SAEs and Other AEs: From Day 1 (Week 0) up to 30 days after the last dose (up to 11 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| JNJ-55308942 | 0/55 (0%) | 2/54 (3.7%) | 6/54 (11.1%) |
| Placebo | 0/61 (0%) | 3/60 (5%) | 10/60 (16.7%) |
| Event | JNJ-55308942 | Placebo |
|---|---|---|
| DepressionPsychiatric disorders | 1/54 | 0/60 |
| Suicide AttemptPsychiatric disorders | 1/54 | 0/60 |
| CholelithiasisHepatobiliary disorders | 0/54 | 1/60 |
| Intentional OverdoseInjury, poisoning and procedural complications | 0/54 | 1/60 |
| Behaviour DisorderPsychiatric disorders | 0/54 | 1/60 |
| ManiaPsychiatric disorders | 0/54 | 1/60 |
| Event | JNJ-55308942 | Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 4/54 | 5/60 |
| HeadacheNervous system disorders | 3/54 | 4/60 |
| DiarrhoeaGastrointestinal disorders | 2/54 | 3/60 |
| VomitingGastrointestinal disorders | 1/54 | 3/60 |
Safety analysis set included all randomized participants who received at least 1 dose of study treatment in the double-blind (DB) treatment phase.
| Age, Continuous(years) | JNJ-55308942 | Placebo | Total |
|---|---|---|---|
| Mean | 39.28 ± 13.603 | 40.18 ± 12.664 | 39.75 ± 13.067 |
| Sex: Female, Male(Participants) | JNJ-55308942 | Placebo | Total |
|---|---|---|---|
| Female | 38 | 33 | 71 |
| Male | 16 | 27 | 43 |
| Ethnicity (NIH/OMB)(Participants) | JNJ-55308942 | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 6 | 9 |
| Not Hispanic or Latino | 50 | 53 | 103 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Race (NIH/OMB)(Participants) | JNJ-55308942 | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 2 |
| Black or African American | 8 | 8 | 16 |
| White | 44 | 50 | 94 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Region of Enrollment(Participants) | JNJ-55308942 | Placebo | Total |
|---|---|---|---|
| Canada | 1 | 0 | 1 |
| Poland | 30 | 30 | 60 |
| Spain | 2 | 5 | 7 |
| United States | 21 | 25 | 46 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Data sharing details ↗ · www.janssen.com
Ran from Jun 2022 to primary completion in May 2024, 23 months.
Results were first posted in Jul 2025, 1 year 1 month after primary completion.
Of 56 phase 2 interventional studies under Bipolar Disorder, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's 23 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: JNJ-55308942
Janssen Pharmaceutica N.V., Belgium →